Imaging for assessment of treatment response in hepatocellular carcinoma: Current update.
Imaging for assessment of treatment response in hepatocellular carcinoma: Current update.
复制标题
DOI：
10.4103/0971-3026.155835
复制
发表时间：
2015-04
期刊：
影响因子：
--
通讯作者：
Sahani DV
中科院分区：
文献类型：
--
作者：
Hayano K;Lee SH;Sahani DV
实体瘤疗效评价标准（RECIST）等形态学方法被认为是癌症治疗中疗效评估的金标准。然而，随着肝癌细胞生长抑制剂和局部介入治疗在临床上的应用越来越多，传统的形态学方法在疗效评估中面临着局限性。因此，人们对用于反应评估的新成像方法越来越感兴趣，该方法可以评估肿瘤生物学，例如血管生理学、纤维化、坏死和代谢。在这篇综述中，我们讨论了各种新的成像方法的反应评估，并比较它们与传统的HCC。
Morphologic methods such as the Response Evaluation Criteria in Solid Tumors (RECIST) are considered as the gold standard for response assessment in the management of cancer. However, with the increasing clinical use of antineoplastic cytostatic agents and locoregional interventional therapies in hepatocellular carcinoma (HCC), conventional morphologic methods are confronting limitations in response assessment. Thus, there is an increasing interest in new imaging methods for response assessment, which can evaluate tumor biology such as vascular physiology, fibrosis, necrosis, and metabolism. In this review, we discuss various novel imaging methods for response assessment and compare them with the conventional ones in HCC.